Corticotropin

Stevens-Johnson Syndrome, Chorioretinitis, Iridocyclitis + 24 more

Treatment

2 FDA approvals

20 Active Studies for Corticotropin

What is Corticotropin

Corticotropin

The Generic name of this drug

Treatment Summary

Corticotropin (also known as ACTH or adrenocorticotropic hormone) is a hormone produced by the pituitary gland. It plays an important role in the communication between the hypothalamus, the pituitary gland, and the adrenal glands.

H.P. Acthar

is the brand name

image of different drug pills on a surface

Corticotropin Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

H.P. Acthar

Corticotropin

2005

4

Approved as Treatment by the FDA

Corticotropin, otherwise known as H.P. Acthar, is approved by the FDA for 2 uses including Infantile Spasms (IS) and Spasms, Infantile .

Infantile Spasms (IS)

Helps manage Infantile Spasms (IS)

Spasms, Infantile

Helps manage Infantile Spasms (IS)

Effectiveness

How Corticotropin Affects Patients

Corticotropin encourages the adrenal glands to produce hormones called corticosteroids. These hormones, including glucocorticoids and androgens, help regulate the body’s daily rhythms. Corticotropin does this by activating certain receptors on the cells of the adrenal gland.

How Corticotropin works in the body

Corticotropin helps diagnose adrenal function by stimulating certain cells to produce steroids. In people with healthy adrenal function, this steroid release increases the amount of cholesterol in the mitochondria. However, corticotropin does not work in patients with primary adrenal insufficiency. The way it works to treat infantile myoclonic seizures is unknown.

When to interrupt dosage

The suggested measure of Corticotropin is contingent upon the diagnosed disorder, including Erythema Multiforme, Sarcoidosis and Diuresis. The dosage also deviates according to the approach of administration (e.g. Injection or Intramuscular; Subcutaneous) as shown in the table underneath.

Condition

Dosage

Administration

Arthritis, Juvenile

, 40.0 units, 80.0 [USP'U]/mL, 80.0 [iU]/mL, 40.0 units/mL

, Gel, Intramuscular; Subcutaneous, Gel - Intramuscular; Subcutaneous, Intramuscular; Intravenous; Subcutaneous, Powder, for solution - Intramuscular; Intravenous; Subcutaneous, Powder, for solution, Injection - Intramuscular; Subcutaneous, Injection, Intravenous, Injection - Intravenous

Stevens-Johnson Syndrome

, 40.0 units, 80.0 [USP'U]/mL, 80.0 [iU]/mL, 40.0 units/mL

, Gel, Intramuscular; Subcutaneous, Gel - Intramuscular; Subcutaneous, Intramuscular; Intravenous; Subcutaneous, Powder, for solution - Intramuscular; Intravenous; Subcutaneous, Powder, for solution, Injection - Intramuscular; Subcutaneous, Injection, Intravenous, Injection - Intravenous

Chorioretinitis

, 40.0 units, 80.0 [USP'U]/mL, 80.0 [iU]/mL, 40.0 units/mL

, Gel, Intramuscular; Subcutaneous, Gel - Intramuscular; Subcutaneous, Intramuscular; Intravenous; Subcutaneous, Powder, for solution - Intramuscular; Intravenous; Subcutaneous, Powder, for solution, Injection - Intramuscular; Subcutaneous, Injection, Intravenous, Injection - Intravenous

Iridocyclitis

, 40.0 units, 80.0 [USP'U]/mL, 80.0 [iU]/mL, 40.0 units/mL

, Gel, Intramuscular; Subcutaneous, Gel - Intramuscular; Subcutaneous, Intramuscular; Intravenous; Subcutaneous, Powder, for solution - Intramuscular; Intravenous; Subcutaneous, Powder, for solution, Injection - Intramuscular; Subcutaneous, Injection, Intravenous, Injection - Intravenous

Nephrotic Syndrome

, 40.0 units, 80.0 [USP'U]/mL, 80.0 [iU]/mL, 40.0 units/mL

, Gel, Intramuscular; Subcutaneous, Gel - Intramuscular; Subcutaneous, Intramuscular; Intravenous; Subcutaneous, Powder, for solution - Intramuscular; Intravenous; Subcutaneous, Powder, for solution, Injection - Intramuscular; Subcutaneous, Injection, Intravenous, Injection - Intravenous

Polymyositis

, 40.0 units, 80.0 [USP'U]/mL, 80.0 [iU]/mL, 40.0 units/mL

, Gel, Intramuscular; Subcutaneous, Gel - Intramuscular; Subcutaneous, Intramuscular; Intravenous; Subcutaneous, Powder, for solution - Intramuscular; Intravenous; Subcutaneous, Powder, for solution, Injection - Intramuscular; Subcutaneous, Injection, Intravenous, Injection - Intravenous

Serum Sickness

, 40.0 units, 80.0 [USP'U]/mL, 80.0 [iU]/mL, 40.0 units/mL

, Gel, Intramuscular; Subcutaneous, Gel - Intramuscular; Subcutaneous, Intramuscular; Intravenous; Subcutaneous, Powder, for solution - Intramuscular; Intravenous; Subcutaneous, Powder, for solution, Injection - Intramuscular; Subcutaneous, Injection, Intravenous, Injection - Intravenous

Arthritis, Gouty

, 40.0 units, 80.0 [USP'U]/mL, 80.0 [iU]/mL, 40.0 units/mL

, Gel, Intramuscular; Subcutaneous, Gel - Intramuscular; Subcutaneous, Intramuscular; Intravenous; Subcutaneous, Powder, for solution - Intramuscular; Intravenous; Subcutaneous, Powder, for solution, Injection - Intramuscular; Subcutaneous, Injection, Intravenous, Injection - Intravenous

Sarcoidosis

, 40.0 units, 80.0 [USP'U]/mL, 80.0 [iU]/mL, 40.0 units/mL

, Gel, Intramuscular; Subcutaneous, Gel - Intramuscular; Subcutaneous, Intramuscular; Intravenous; Subcutaneous, Powder, for solution - Intramuscular; Intravenous; Subcutaneous, Powder, for solution, Injection - Intramuscular; Subcutaneous, Injection, Intravenous, Injection - Intravenous

Dermatomyositis

, 40.0 units, 80.0 [USP'U]/mL, 80.0 [iU]/mL, 40.0 units/mL

, Gel, Intramuscular; Subcutaneous, Gel - Intramuscular; Subcutaneous, Intramuscular; Intravenous; Subcutaneous, Powder, for solution - Intramuscular; Intravenous; Subcutaneous, Powder, for solution, Injection - Intramuscular; Subcutaneous, Injection, Intravenous, Injection - Intravenous

Erythema Multiforme

, 40.0 units, 80.0 [USP'U]/mL, 80.0 [iU]/mL, 40.0 units/mL

, Gel, Intramuscular; Subcutaneous, Gel - Intramuscular; Subcutaneous, Intramuscular; Intravenous; Subcutaneous, Powder, for solution - Intramuscular; Intravenous; Subcutaneous, Powder, for solution, Injection - Intramuscular; Subcutaneous, Injection, Intravenous, Injection - Intravenous

induction of Diuresis

, 40.0 units, 80.0 [USP'U]/mL, 80.0 [iU]/mL, 40.0 units/mL

, Gel, Intramuscular; Subcutaneous, Gel - Intramuscular; Subcutaneous, Intramuscular; Intravenous; Subcutaneous, Powder, for solution - Intramuscular; Intravenous; Subcutaneous, Powder, for solution, Injection - Intramuscular; Subcutaneous, Injection, Intravenous, Injection - Intravenous

Diuresis

, 40.0 units, 80.0 [USP'U]/mL, 80.0 [iU]/mL, 40.0 units/mL

, Gel, Intramuscular; Subcutaneous, Gel - Intramuscular; Subcutaneous, Intramuscular; Intravenous; Subcutaneous, Powder, for solution - Intramuscular; Intravenous; Subcutaneous, Powder, for solution, Injection - Intramuscular; Subcutaneous, Injection, Intravenous, Injection - Intravenous

Optic Neuritis

, 40.0 units, 80.0 [USP'U]/mL, 80.0 [iU]/mL, 40.0 units/mL

, Gel, Intramuscular; Subcutaneous, Gel - Intramuscular; Subcutaneous, Intramuscular; Intravenous; Subcutaneous, Powder, for solution - Intramuscular; Intravenous; Subcutaneous, Powder, for solution, Injection - Intramuscular; Subcutaneous, Injection, Intravenous, Injection - Intravenous

Acute Coryza

, 40.0 units, 80.0 [USP'U]/mL, 80.0 [iU]/mL, 40.0 units/mL

, Gel, Intramuscular; Subcutaneous, Gel - Intramuscular; Subcutaneous, Intramuscular; Intravenous; Subcutaneous, Powder, for solution - Intramuscular; Intravenous; Subcutaneous, Powder, for solution, Injection - Intramuscular; Subcutaneous, Injection, Intravenous, Injection - Intravenous

Psoriatic Arthritis

, 40.0 units, 80.0 [USP'U]/mL, 80.0 [iU]/mL, 40.0 units/mL

, Gel, Intramuscular; Subcutaneous, Gel - Intramuscular; Subcutaneous, Intramuscular; Intravenous; Subcutaneous, Powder, for solution - Intramuscular; Intravenous; Subcutaneous, Powder, for solution, Injection - Intramuscular; Subcutaneous, Injection, Intravenous, Injection - Intravenous

Rheumatoid Arthritis

, 40.0 units, 80.0 [USP'U]/mL, 80.0 [iU]/mL, 40.0 units/mL

, Gel, Intramuscular; Subcutaneous, Gel - Intramuscular; Subcutaneous, Intramuscular; Intravenous; Subcutaneous, Powder, for solution - Intramuscular; Intravenous; Subcutaneous, Powder, for solution, Injection - Intramuscular; Subcutaneous, Injection, Intravenous, Injection - Intravenous

Lupus

, 40.0 units, 80.0 [USP'U]/mL, 80.0 [iU]/mL, 40.0 units/mL

, Gel, Intramuscular; Subcutaneous, Gel - Intramuscular; Subcutaneous, Intramuscular; Intravenous; Subcutaneous, Powder, for solution - Intramuscular; Intravenous; Subcutaneous, Powder, for solution, Injection - Intramuscular; Subcutaneous, Injection, Intravenous, Injection - Intravenous

Ankylosing Spondylitis

, 40.0 units, 80.0 [USP'U]/mL, 80.0 [iU]/mL, 40.0 units/mL

, Gel, Intramuscular; Subcutaneous, Gel - Intramuscular; Subcutaneous, Intramuscular; Intravenous; Subcutaneous, Powder, for solution - Intramuscular; Intravenous; Subcutaneous, Powder, for solution, Injection - Intramuscular; Subcutaneous, Injection, Intravenous, Injection - Intravenous

Allergic Conjunctivitis (AC)

, 40.0 units, 80.0 [USP'U]/mL, 80.0 [iU]/mL, 40.0 units/mL

, Gel, Intramuscular; Subcutaneous, Gel - Intramuscular; Subcutaneous, Intramuscular; Intravenous; Subcutaneous, Powder, for solution - Intramuscular; Intravenous; Subcutaneous, Powder, for solution, Injection - Intramuscular; Subcutaneous, Injection, Intravenous, Injection - Intravenous

Warnings

Corticotropin Contraindications

Condition

Risk Level

Notes

Postoperative

Do Not Combine

Keratitis, Herpetic

Do Not Combine

Pulse Frequency

Do Not Combine

A History of Gastric or Duodenal Ulcers

Do Not Combine

Adrenocortical Hyperfunction

Do Not Combine

Scleroderma

Do Not Combine

Hypertensive disease

Do Not Combine

Addison Disease

Do Not Combine

Mycoses

Do Not Combine

Osteoporosis

Do Not Combine

Congestive Heart Failure

Do Not Combine

Pulse Frequency

Do Not Combine

Peptic Ulcer

Do Not Combine

There are 20 known major drug interactions with Corticotropin.

Common Corticotropin Drug Interactions

Drug Name

Risk Level

Description

2-Methoxyethanol

Major

The risk or severity of adverse effects can be increased when Corticotropin is combined with 2-Methoxyethanol.

9-(N-methyl-L-isoleucine)-cyclosporin A

Major

The risk or severity of adverse effects can be increased when Corticotropin is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.

Abemaciclib

Major

The metabolism of Abemaciclib can be increased when combined with Corticotropin.

Abetimus

Major

The risk or severity of adverse effects can be increased when Corticotropin is combined with Abetimus.

Acalabrutinib

Major

The metabolism of Acalabrutinib can be increased when combined with Corticotropin.

image of a doctor in a lab doing drug, clinical research

Corticotropin Novel Uses: Which Conditions Have a Clinical Trial Featuring Corticotropin?

27 active exploratory trials are being conducted to evaluate the potential of Corticotropin in providing relief from Inflammation, Sarcoidosis and Polymyositis.

Condition

Clinical Trials

Trial Phases

Arthritis, Juvenile

1 Actively Recruiting

Not Applicable

Lupus

65 Actively Recruiting

Phase 2, Not Applicable, Phase 1, Phase 3, Phase 4, Early Phase 1

Stevens-Johnson Syndrome

1 Actively Recruiting

Phase 1

Serum Sickness

0 Actively Recruiting

Multiple Sclerosis

0 Actively Recruiting

Optic Neuritis

3 Actively Recruiting

Phase 2, Phase 3

Allergic Conjunctivitis (AC)

1 Actively Recruiting

Phase 2

Chorioretinitis

0 Actively Recruiting

Nephrotic Syndrome

5 Actively Recruiting

Phase 2, Not Applicable, Phase 3

Iritis

0 Actively Recruiting

Iridocyclitis

0 Actively Recruiting

Diuresis

0 Actively Recruiting

Sarcoidosis

10 Actively Recruiting

Phase 4, Phase 2, Not Applicable, Phase 3

induction of Diuresis

0 Actively Recruiting

Proteinuria

0 Actively Recruiting

Erythema Multiforme

0 Actively Recruiting

Psoriasis

0 Actively Recruiting

Rheumatoid Arthritis

55 Actively Recruiting

Not Applicable, Phase 4, Phase 3, Phase 2, Phase 1

Arthritis, Gouty

0 Actively Recruiting

Psoriatic Arthritis

30 Actively Recruiting

Phase 3, Not Applicable, Phase 1, Phase 4, Phase 2

Corticotropin Reviews: What are patients saying about Corticotropin?

3.3

Patient Review

12/16/2013

Corticotropin for Inflammation of the Lining of a Joint

image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about corticotropin

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What does the corticotropin hormone do?

"Corticotropin-releasing hormone (CRH) is a peptide hormone that activates the synthesis and release of adrenocorticotropic hormone (ACTH) from the pituitary gland. CRH affects our response to stress, addiction and depression."

Answered by AI

Is corticotropin the same as cortisol?

"When cortisol levels are low, a hormone called corticotrophin-releasing hormone (CRH) is released from a group of cells in the hypothalamus. This hormone then stimulates the pituitary gland to secrete adrenocorticotropic hormone (ACTH) into the bloodstream."

Answered by AI

Is corticotropin a steroid?

"The effects of corticotropin are similar to those of the steroids (hydrocortisone, androgens) that it causes to be released from the adrenal cortex. If corticotropin is taken in large doses for a long time, it can cause the clinical picture known as Cushing's syndrome."

Answered by AI

Is corticotropin a drug?

"Corticotropin is a hormone that can be used to treat a variety of conditions, including multiple sclerosis, psoriatic or rheumatoid arthritis, ankylosing spondylitis, lupus, severe allergic reactions, breathing disorders, and inflammatory conditions of the eyes."

Answered by AI

Clinical Trials for Corticotropin

Image of National Institutes of Health Clinical Center in Bethesda, United States.

Meal Macronutrients for Blood Fat Levels

18 - 120
All Sexes
Bethesda, MD

Background: Abnormal fats in the blood can lead to many problems, including heart disease. Researchers want to learn more about how eating meals with different levels of nutrients affects fats in the blood. Specifically, they want to study people with too much body fat, too little body fat, and a kidney problem called nephrotic syndrome. Objective: To learn more about how different types of foods affect fat levels in the blood. Eligibility: People aged 18 years or older with a health condition that affects how their body handles fats. Healthy volunteers are also needed. Design: Participants will have 2 overnight stays in the clinic within 6 months. At each visit, after staying overnight, they will eat a breakfast casserole. At 1 visit, breakfast will be a high-fat, low carbohydrate meal. At the other, it will be a high-carbohydrate, low-fat meal. Participants will have a tube inserted into a vein in their arm. They will have blood drawn via the tube 12 times in 8 hours: 2 times before they eat the breakfast and 10 times after. Participants will have other tests during their stays: * A resting metabolic test captures the air they exhale and measures how much energy they use at rest. * A dual energy X-ray absorptiometry (DXA) scan measures how much fat and muscle they have. * A Fibroscan is a special type of ultrasound of the liver. * A body surface scan uses lasers to measure the total area of the body. * A bioelectric impedance (BIS) exam measures how fast small electric currents move through their body. Participants may opt to have a third visit. At this visit, the breakfast will be high in protein.

Phase 2
Waitlist Available

National Institutes of Health Clinical Center

Rebecca J Brown, M.D.

Have you considered Corticotropin clinical trials?

We made a collection of clinical trials featuring Corticotropin, we think they might fit your search criteria.
Go to Trials
Image of Investigative Site in Beverly Hills, United States.

VENT-03 for Lupus

18 - 80
All Sexes
Beverly Hills, CA

The goal of this clinical trial is to learn if VENT-03 works to treat patients with cutaneous lupus erythematosus (CLE) who may or may not have systemic lupus erythematosus (SLE). Another goal is to learn about the safety of VENT-03 and how it is processed by the body. The main questions it aims to answer are: * Does VENT-03 affect the activity and severity of CLE? * What side effects do participants have when taking VENT-03? Researchers will compare VENT-03 to a placebo (a look-alike substance that contains no drug) to see if VENT-03 works to treat patients with CLE. Participants will: * Take VENT-03 or a placebo e for 4 weeks, then all participants will switch to VENT-03 for another 8 weeks; * Visit the clinic once a month for checkups and tests.

Phase 2
Recruiting

Investigative Site (+9 Sites)

Ventus Therapeutics U.S., Inc.

Have you considered Corticotropin clinical trials?

We made a collection of clinical trials featuring Corticotropin, we think they might fit your search criteria.
Go to Trials
Image of Weill Cornell Medical College in New York, United States.

Health Coaching for Rheumatoid Arthritis

18+
All Sexes
New York, NY

The goal of this clinical trial is to learn if peer coaching works to reduce levels of anxiety and/or depression in adults diagnosed with Rheumatoid Arthritis (RA). The main questions it aims to answer are: Do people with RA who complete the intervention with a peer coach have lower levels of anxiety and/or depression at 6 months from baseline? Do people with RA who complete the intervention with a peer coach have lower levels of anxiety and/or depression at 6 months compared to those in the control arm? Researchers will compare the peer coaching intervention to an active-control arm (where people without RA coach participants on general health and nutrition topics) to see if peer coaching works to reduce anxiety and/or depression. Participants will meet with a coach every week for 9 weeks and complete several surveys before, during and after the intervention

Recruiting
Has No Placebo

Weill Cornell Medical College

Iris Y Navarro-Millán, MD

Bristol-Myers Squibb

Image of Humana Healthcare Research, Inc. in Louisville, United States.

Academic Detailing for Rheumatoid Arthritis

Any Age
All Sexes
Louisville, KY

The goal of this trial is to learn if an interactive evidence-based educational outreach visits to clinicians who prescribe biologics change prescribing of biosimilar medications. The main questions it aims to answer are: 1. Do educational outreach visits lead to a higher number of prescriptions for biosimilar versions of adalimumab? 2. Do in-person or virtual visits work better? Researchers will compare clinicians offered the educational outreach visit to those who are not offered the visit to see if there is a difference in prescribing of biosimilar versions of adalimumab instead of the original brand-name version. Participants will be offered the chance to meet with a trained clinician who will provide educational information tailored to their knowledge and attitudes on the topic. They will also be provided an educational brochure and patient educational materials.

Waitlist Available
Has No Placebo

Humana Healthcare Research, Inc. (+1 Sites)

Image of Truway Health, Inc. www.truwayhealth.com (401 E 34th Street, S11P, New York, NY 10016) in New York, United States.

Electromagnetic Resonance Therapy for Autoimmune Diseases

Any Age
All Sexes
New York, NY

The ImmuneNet study is a Phase I/II clinical trial sponsored by Truway Health, Inc. It will test whether gentle, low-frequency electromagnetic resonance (LF-EMR) can influence how immune cells communicate and synchronize with each other. The goal is to see if this "quantum-synaptic" signaling effect can help stabilize immune activity and reduce the number of autoimmune flare-ups in people living with conditions such as lupus, rheumatoid arthritis, or multiple sclerosis. Participants will receive either an active or a sham (placebo) LF-EMR session three times per week for twelve weeks. Each session is completely non-invasive. Blood samples will be collected to study cytokines (immune-system messenger molecules), gene-expression patterns, and electrical field coherence among immune cells. A machine-learning system will analyze these data to predict inflammation patterns and guide individualized treatment settings. All participant data will be securely recorded and time-stamped to ensure transparency and privacy. The expected outcome of the study is a measurable reduction in autoimmune flare frequency and symptom severity, along with improved understanding of how electromagnetic signaling might safely regulate immune function.

Phase 1 & 2
Waitlist Available

Truway Health, Inc. www.truwayhealth.com (401 E 34th Street, S11P, New York, NY 10016)

Gavin Solomon, President & CEO

Truway Health, Inc.

Have you considered Corticotropin clinical trials?

We made a collection of clinical trials featuring Corticotropin, we think they might fit your search criteria.
Go to Trials